SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE is trending as the community rallies around the project's longevity and continued development, highlighting its live staking on Bifinance, play-to-earn games, and Forbes feature. Community members emphasize that $BROKE is more than just a meme coin, focusing on its strong community and active development team within the Solana ecosystem.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is gaining attention, particularly within the Phantom Wallet community, where it's being touted as a potential gem. The community is using terms like "moon," "rocket," and "breakout" to describe the token's recent price action and momentum.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending amid discussions about Bitcoin's recent price movements, particularly its approach to all-time highs and potential for further gains. Community members are weighing in on factors like institutional investment, regulatory developments, and the impact of potential government shutdowns, while also debating whether Bitcoin is a safe haven asset or a speculative investment. There is active speculation on short squeezes, market manipulation, and potential rotation into other assets like gold.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses its potential, recent news around Ripple, and possible utility. Some are focused on the potential impact of XRP ETFs, while others highlight Ripple's partnerships and real-world use cases. Community members are also discussing XRP's price action and potential decoupling from Bitcoin.

Jump into the crypto fun with $SOLCAT! Our token features a savvy cat wearing a fabulous Solana hat, offering super cool adventures in the world of meme coins.

CatSolHat

CatSolHat ($SOLCAT) is trending as the community rallies around this Solana-based meme coin. The coin is being touted as 'Solana's sleekest predator' as social media users encourage others to 'join the pride'. It's also being discussed in relation to other meme coins like $PEPE.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to upcoming FDA decision on Revuforj for relapsed/refractory AML, with the community actively debating the potential impact of approval and existing safety warnings. Discussions revolve around the drug's market potential, comparison to competitors like Kura, and speculation about a possible buyout. Investors are weighing potential gains against concerns about short positions and market manipulation.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors closely monitor the Gen AI Summit for potential catalysts, with speculation around new contracts and strategic partnerships driving community interest; analysts have increased price targets, further fueling the bullish sentiment. Discussions also focus on the company's competitive positioning in the AI data market and its potential for expansion into enterprise and government sectors. Despite some concerns about high valuation, the overall tone remains optimistic, as investors eagerly await further developments and Q3 earnings results.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community anticipates potential listings on major exchanges like Coinbase and Crypto.com, speculating about a possible surge. Discussions also revolve around its relationship with Dogecoin and potential for significant gains in the coming years, with some comparing its current trajectory to Shiba Inu's earlier days.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to increased interest in AI-driven healthcare solutions, particularly after presenting at the GITEX Global conference in Dubai. The community is focused on the stock's high short interest and potential for a short squeeze, referencing NVIDIA's investment as a positive signal. Some anticipate news or catalysts that could trigger a significant upward move.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses meme coins built on the Solana blockchain, particularly those associated with Phantom Wallet, such as $SOLYCAT and $BALLIN. Broader conversations touch on staking opportunities and potential institutional adoption with mentions of Fidelity. Sentiment suggests excitement around new projects and the overall potential of the Solana ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc...

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

Will BMY's Growth Portfolio Drive Third-Quarter Results? 

Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?

CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	6.37%
50-Day Moving Average	$24.88
Beta	0.42
Avg. Volume	52.42M
PE Ratio	13.17

52-Week High	$29.17
52-Week Low	$20.92
Market Capitalization	$140.77B
EPS (Annual)	$1.41
Price to Book	1.59
Revenue Per Employee	$785,518.52
Enterprise Value/EBITDA	N/A

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc